Highlights Newsletter 3
This newsletter presents you the following key sessions:
5. Docetaxel as a radiosensitiser in cisplatin-ineligible patients with head and neck cancer
This newsletter presents you the following key sessions:
5. Docetaxel as a radiosensitiser in cisplatin-ineligible patients with head and neck cancer
Medical writer
Medical writer